UNASSIGNED: Patients after first LT were randomized to C2 or T0. tBPAR, patient- and graft survival, safety and tolerability were the main endpoints, with analysis by Fisher test, Kaplan-Meier survival analysis and log-rank test.
UNASSIGNED: In intention-to-treat analysis 84 patients on C2 and 85 on T0 were included. Cumulative incidence of tBPAR C2 vs. T0 was 17.7% vs. 8.4% at 3 months (p=0.104), and 21.9% vs. 9.7% at 6 and 12 months (p=0.049). One-year cumulative mortality C2 vs. T0 was 15.5% vs. 5.9% (p=0.049) and graft loss 23.8% vs. 9.4% (p=0.015). Serum triglyceride and LDL-cholesterol was lower with T0 than with C2. Incidence of diarrhea in T0 vs, C2 was 64% vs. 31% (p≤0.001), with no other differences in safety and tolerability.
UNASSIGNED: In the first year after LT immunosuppression with T0 leads to less tBPAR and better patient-/re-transplant-free survival as compared to C2.
■第一次LT后的患者被随机分为C2或T0。tBPAR,患者和移植物存活,安全性和耐受性是主要终点,通过费舍尔检验分析,Kaplan-Meier生存分析和对数秩检验。
■在意向治疗分析中,纳入了84例C2和85例T0患者。tBPARC2的累积发病率与T0为17.7%vs.3个月时为8.4%(p=0.104),和21.9%与6个月和12个月时为9.7%(p=0.049)。一年累计死亡率C2vs.T0为15.5%vs.5.9%(p=0.049)和移植物损失23.8%9.4%(p=0.015)。T0的血清甘油三酯和LDL-胆固醇低于C2。T0的腹泻发生率vs,C2为64%vs.31%(p≤0.001),在安全性和耐受性方面没有其他差异。
■在LT免疫抑制后的第一年,与C2相比,T0导致更少的tBPAR和更好的患者/再移植生存。